Monogram Technologies (MGRM) Registration Filing summary

Company overview and business model

• AI-driven robotics company focused on orthopedic surgery, aiming to enable patient-optimized implants at scale using 3D printing, machine vision, AI, and robotics.

• mBôs robotic surgical system is designed for autonomous, high-precision knee implant procedures; FDA clearance obtained for mPress implants, with plans to seek 510(k) clearance for robotic products in the second half of 2024.

• Product portfolio includes robotic surgical equipment, implants, tissue ablation tools, navigation consumables, and related software.

Financial performance and metrics

• Common stock listed on Nasdaq Capital Market under the symbol “MGRM”; last reported sale price was $1.99 on May 31, 2024.

• Company qualifies as a smaller reporting company and emerging growth company, allowing for reduced public company reporting requirements.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including working capital, operating expenses, and capital expenditures.

• May allocate a portion of proceeds to acquire or invest in complementary businesses or products, though no current commitments exist.

• Unused proceeds will be invested in short-term, investment-grade, interest-bearing instruments.